Home World News HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours World News HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 744 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR New Way to Classify Meningioma Brain Tumors Suggests Potential Treatments June 17, 2022 Study Suggests that Cancer Patients Who Eat Peanuts Frequently May Be... August 5, 2021 NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration February 28, 2019 Prize winning early detection research October 7, 2021 Load more HOT NEWS Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,... First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma The ‘major conditions strategy’: will ministers fail to give cancer the... The art of practicing sustainable science
